HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Chronic urotensin II infusion enhances macrophage foam cell formation and atherosclerosis in apolipoprotein E-knockout mice.

AbstractOBJECTIVE:
Our recent studies have indicated that urotensin II, the most potent vasoconstrictor peptide identified to date, potentiates human macrophage foam cell formation and vascular smooth muscle cell proliferation, and its levels are increased in the plasma of hypertensive patients with carotid atherosclerotic plaques. In the present study, we investigated the enhancing effect of urotensin II on atherosclerosis in apolipoprotein E-knockout mice and its suppression by 4-aminoquinoline, an urotensin II receptor-selective antagonist.
METHODS:
Urotensin II, urotensin II + 4-aminoquinoline, or vehicle was infused for 4 weeks through an osmotic mini-pump into 9-week-old apolipoprotein E-knockout mice on a high-fat diet. Aortic atherosclerosis and foam cell formation in exudate peritoneal macrophages were examined.
RESULTS:
Atherosclerotic lesions as well as plasma levels of urotensin II, reactive oxygen species, and oxidized low-density lipoprotein and oxidized low-density lipoprotein-induced foam cell formation were significantly greater in urotensin II-infused mice than vehicle-infused controls. Western blotting analysis showed increased expression of scavenger receptors (CD36 and scavenger receptor class A) and acyl-CoA:cholesterol acyltransferase-1 in these macrophages. Increases in these parameters were significantly reduced by addition of 4-aminoquinoline. In apolipoprotein E-knockout mice even without urotensin II infusion, the treatment with 4-aminoquinoline for 8 weeks significantly prevented the development of atherosclerotic lesions.
CONCLUSION:
Our results provide the first evidence that increased plasma urotensin II level stimulates oxidized low-density lipoprotein and reactive oxygen species production and macrophage foam cell formation via increased expression of CD36, scavenger receptor class A, and acyl-CoA:cholesterol acyltransferase-1, contributing to the development of atherosclerosis in apolipoprotein E-deficient mice. Urotensin II receptor antagonism may be a promising therapeutic strategy against atherosclerosis.
AuthorsYuji Shiraishi, Takuya Watanabe, Toshiaki Suguro, Masaharu Nagashima, Rina Kato, Shigeki Hongo, Hiroyuki Itabe, Akira Miyazaki, Tsutomu Hirano, Mitsuru Adachi
JournalJournal of hypertension (J Hypertens) Vol. 26 Issue 10 Pg. 1955-65 (Oct 2008) ISSN: 0263-6352 [Print] England
PMID18806619 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Apolipoproteins E
  • CD36 Antigens
  • Lipoproteins, LDL
  • Reactive Oxygen Species
  • Scavenger Receptors, Class A
  • Urotensins
  • oxidized low density lipoprotein
  • urotensin II
  • Sterol O-Acyltransferase
  • sterol O-acyltransferase 1
Topics
  • Animals
  • Apolipoproteins E (genetics)
  • Atherosclerosis (physiopathology)
  • CD36 Antigens (metabolism)
  • Diet, Atherogenic
  • Foam Cells (physiology)
  • Lipoproteins, LDL (metabolism)
  • Male
  • Mice
  • Mice, Knockout
  • Reactive Oxygen Species (metabolism)
  • Scavenger Receptors, Class A (metabolism)
  • Sterol O-Acyltransferase (metabolism)
  • Urotensins (physiology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: